SCHEDULE 13G: Lynx1 Capital Management and Weston Nichols Disclose 5.2% Stake in Allogene Therapeutics
Beneficial Ownership Disclosure
Lynx1 Capital Management LP and Weston Nichols have jointly disclosed a beneficial ownership of 5.2% in Allogene Therapeutics, Inc., as of December 31, 2024.
Summary
- Lynx1 Capital Management LP and Weston Nichols, collectively referred to as the "Reporting Persons," have filed a Schedule 13G indicating beneficial ownership in Allogene Therapeutics, Inc.
- As of December 31, 2024, the Reporting Persons beneficially own an aggregate of 10,874,723 shares of Common Stock of Allogene Therapeutics, Inc.
- This ownership represents 5.2% of the total outstanding Common Stock of Allogene Therapeutics, Inc.
- The percentage is calculated based on 209,672,091 shares of Common Stock outstanding as of November 1, 2024, as reported in the Company's Quarterly Report on Form 10-Q.
- Both Lynx1 Capital Management LP and Weston Nichols share voting and dispositive power over all 10,874,723 shares.
- The filing certifies that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would indicate a positive or negative sentiment regarding the issuer's performance or outlook.
Future Outlook
NA
Industry Context
This filing indicates a significant passive investment by Lynx1 Capital Management LP and Weston Nichols in Allogene Therapeutics, Inc., a company operating in the biotechnology or pharmaceutical sector, specifically focused on cell therapies. Such disclosures are common for institutional investors crossing the 5% ownership threshold.
Stakeholder Impact
- Shareholders: The disclosure of a new significant passive investor may be viewed positively by some shareholders as a vote of confidence, while others may monitor for potential future changes in investment strategy.
Key Dates
| Date | Description |
|---|---|
| 2024-11-01 | Date as of which 209,672,091 shares of Common Stock were reported outstanding in the Company's 10-Q. |
| 2024-11-07 | Date Allogene Therapeutics, Inc. filed its Quarterly Report on Form 10-Q for the period ended September 30, 2024. |
| 2024-12-31 | Date of event which requires the filing of this Schedule 13G statement. |
| 2025-02-14 | Date the Joint Filing Agreement and Schedule 13G were signed. |
Keywords
Allogene Therapeutics, Lynx1 Capital Management, Weston Nichols, Schedule 13G, Beneficial Ownership, Common Stock, Investment Management, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.